Janux Therapeutics JANX Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's quick ratio?
- Janux Therapeutics (JANX) reported quick ratio of 17× in Q1 2026.
- How has Janux Therapeutics's quick ratio changed year-over-year?
- Janux Therapeutics's quick ratio decreased by 70.9% year-over-year, from 58.5× to 17×.
- What is the long-term trend for Janux Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Janux Therapeutics's quick ratio has grown at a 50.5% compound annual growth rate (CAGR), from 5× to 39×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.